| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VALERITAS Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 328,40 | +0,06 % | Dividendenbekanntmachungen (14.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BROOKFIELD CORPORATION CA11271J1075 0,07 USD 0,0603 EUR BROOKFIELD WEALTH SOLUTIONS LTD BMG174341047 0,07 USD 0,0603 EUR CALAMOS... ► Artikel lesen | |
| THERMO FISHER | 565,00 | -0,35 % | Dividendenbekanntmachungen (15.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AKVA GROUP ASA NO0003097503 1 NOK 0,0927 EUR ALEXANDRIA GROUP OYJ FI4000153465 - 0,35 EUR ALTRIA GROUP INC US02209S1033 1,11 USD 0... ► Artikel lesen | |
| TELADOC HEALTH | 5,460 | -0,36 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| RESMED | 201,60 | +2,88 % | ResMed Inc. (RMD)'s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures | ||
| HENRY SCHEIN | 74,50 | +0,68 % | Henry Schein Inc. Profit Advances In Q2 | MELVILLE (dpa-AFX) - Henry Schein Inc. (HSIC) announced earnings for its second quarter that Increases, from last yearThe company's bottom line totaled $94 million, or $0.82 per share. This... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| ZIMMER BIOMET | 82,74 | -0,34 % | Is Zimmer Biomet Stock Underperforming the Nasdaq? | ||
| PETMED EXPRESS | 1,358 | -2,86 % | PetMed Express, Inc.: PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition | DELRAY BEACH, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of consumer and e-commerce... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | +1,36 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| QUIDELORTHO | 9,076 | -1,99 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| QUEST DIAGNOSTICS | 213,40 | -0,56 % | Humanity Health Inc.; Quest Diagnostics: Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com | Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platformLONDON, Aug.... ► Artikel lesen | |
| VERU | 2,395 | -0,62 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| SENSEONICS | 7,850 | -5,99 % | Senseonics sees activist investor take a major stake | ||
| TEMPEST THERAPEUTICS | 0,965 | -0,35 % | Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in... ► Artikel lesen |